IN8bio Inc. is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of gamma-delta T cell therapies aimed at treating cancer. Leveraging its proprietary DeltEx™ platform, the company develops innovative cell therapies employing various approaches, including allogeneic, autologous, induced pluripotent stem cell (iPSC), and genetically modified gamma-delta T cells. These specialized immune cells have unique capabilities to distinguish healthy from diseased tissue, functioning as a bridge between innate and adaptive immunity with potent antitumor activity. IN8bio’s lead candidates include INB-400 and INB-200, in clinical trials targeting glioblastoma, and INB-100, aimed at hematologic malignancies in patients undergoing bone marrow transplantation. Beyond these, its pipeline encompasses multiple preclinical and discovery-stage programs focused on solid and hematological tumors, reflecting its commitment to advancing next-generation cellular immunotherapies and striving toward the elimination of cancer.